摘要:
The invention relates to (E)-5-(2-bromovinyl)-uridine and its derivatives of general formula VI, ##STR1## wherein R.sup.1 stands for a hydrogen atom, C.sub.1-8 alkanoyl group, benzoyl group or a benzoyl group substituted in para position either with a C.sub.1-4 alkyl group or a halogen atom, and a process for preparing them by brominating 2',3',5'-tri-O-acyl-5-ethyl-uridine of general formula IV, ##STR2## wherein R is identical with R.sup.1, except where R.sup.1 stands for a hydrogen atom, dehydrohalogenating the resulting dibromo compound of general formula V ##STR3## and optionally deacylating it. The resulting compounds of general formula VI are exhibiting significant potency against Herpes simplex virus species and are of remarkably low acute toxicity.
摘要:
The invention relates to an externally applicable, antiviral pharmaceutical composition accumulating in the skin for treating herpes infections, which composition comprises 0.2-5% by mass of 5-isopropyl-2'-.beta.-deoxyuridine admixed with carriers, diluents and/or other additives conventionally used in the production of pharmaceutical compositions for external use.
摘要:
The invention relates to new tetrahydro-1,2,4-oxadiazin-5-one derivatives having a CNS activity. More particularly, the invention concerns new N.sup.4 -substituted tetrahydro-1,2,4-oxadiazin-5-ones of the formula (1) ##STR1## wherein R.sup.2 is benzyloxycarbonyl or alkylcarbonyl containing 1 to 4 carbon atoms in the alkyl moiety, preferably acetyl;R.sup.3 is phenyl optionally substituted with 1 to 3 lower alkoxy groups; andR.sup.4 is an aliphatic or cyclic alkyl group having 1 to 11 carbon atoms, hydroxymethyl, halomethyl or acyloxymethyl.According to another aspect of the invention there are provided processes for the preparation of compounds of formula (1). Still another aspect of the invention is a pharmaceutical composition which comprises as active ingredient a compound of formula (1).
摘要:
The invention relates to new hexitols having the general formula (I) and (II), ##STR1## wherein the hexitol skeleton is dulcitol, mannitol or iditol,X represents halogen, preferably bromine,R is a saturated or unsaturated C.sub.4-10 alkylcarbonyl group which also contains a free carboxy group, andR.sup.1 is hydrogen, a saturated or unsaturated C.sub.4-10 alkylcarbonyl group which also contains a free carboxy group, a saturated or unsaturated C.sub.2-10 alkylcarbonyl group, a saturated or unsaturated C.sub.4-10 alkylcarbonyl group which also contains an alkoxycarbonyl group, or a saturated or unsaturated C.sub.8-10 aralkylcarbonyl group,and salts of these compounds. The new compounds according to the invention have tumor-inhibiting affects.The above compounds are prepared according to the invention so that(a) a compound of the general formula (IX), whereinthe hexitol skeleton is dulcitol, mannitol or iditol,Q is a saturated or unsaturated C.sub.11-17 alkylcarbonyl group which also contains a benzyloxycarbonyl group, andQ.sup.1 is hydrogen, a saturated or unsaturated C.sub.2-10 alkylcarbonyl group, a saturated or unsaturated C.sub.4-10 alkylcarbonyl group which also contains an alkoxycarbonyl group, a saturated or unsaturated C.sub.11-17 alkylcarbonyl group which also contains a benzyloxycarbonyl group, or a saturated or unsaturated C.sub.8-10 aralkylcarbonyl group, is hydrogenated in an anhydrous solvent in the presence of a weakly active catalyst which does not affect the epoxide ring, or(b) a 1,2-5,6-dianhydrohexitol of the general formula (X), wherein the hexitol skeleton is dulcitol, mannitol or iditol, is reacted with a dicarboxylic acid anhydride of the general formula (XI), wherein A is a C.sub.2-10 alkyl, aralkyl or aryl group, or(c) a compound of the general formula (I) is reacted with an alkali halide and/or hydrogen halide. ##STR2##